Literature DB >> 8064223

Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS.

M M Wurfel1, S T Kunitake, H Lichenstein, J P Kane, S D Wright.   

Abstract

Lipoproteins isolated from normal human plasma can bind and neutralize bacterial lipopolysaccharide (LPS) and may represent an important mechanism in host defense against gram-negative septic shock. Recent studies have shown that experimentally elevating the levels of circulating high-density lipoproteins (HDL) provides protection against death in animal models of endotoxic shock. We sought to define the components of HDL that are required for neutralization of LPS. To accomplish this we have studied the functional neutralization of LPS by native and reconstituted HDL using a rapid assay that measures the CD14-dependent activation of leukocyte integrins on human neutrophils. We report here that reconstituted HDL particles (R-HDL), prepared from purified apolipoprotein A-I (apoA-I) combined with phospholipid and free cholesterol, are not sufficient to neutralize the biologic activity of LPS. However, addition of recombinant LPS binding protein (LBP), a protein known to transfer LPS to CD14 and enhance responses of cells to LPS, enabled prompt binding and neutralization of LPS by R-HDL. Thus, LBP appears capable of transferring LPS not only to CD14 but also to lipoprotein particles. In contrast with R-HDL, apoA-I containing lipoproteins (LpA-I) isolated from plasma by selected affinity immunosorption (SAIS) on an anti-apoA-I column, neutralized LPS without addition of exogenous LBP. Several lines of evidence demonstrated that LBP is a constituent of LpA-I in plasma. Passage of plasma over an anti-apoA-I column removed more than 99% of the LBP detectable by ELISA, whereas 31% of the LBP was recovered by elution of the column. Similarly, the ability of plasma to enable activation of neutrophils by LPS (LBP/Septin activity) was depleted and recovered by the same process. Furthermore, an immobilized anti-LBP monoclonal antibody coprecipitated apoA-I. The results described here suggest that in addition to its ability to transfer LPS to CD14, LBP may also transfer LPS to lipoproteins. Since LBP appears to be physically associated with lipoproteins in plasma, it is positioned to play an important role in the neutralization of LPS.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8064223      PMCID: PMC2191628          DOI: 10.1084/jem.180.3.1025

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  37 in total

1.  RESTORATION OF ENDOTOXIN ACTIVITY FOLLOWING ALTERATION BY PLASMA.

Authors:  J A RUDBACH; A G JOHNSON
Journal:  Nature       Date:  1964-05-23       Impact factor: 49.962

2.  Binding of transition metals by apolipoprotein A-I-containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins.

Authors:  S T Kunitake; M R Jarvis; R L Hamilton; J P Kane
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

3.  Isolation and characterization of a phospholipid transfer protein (LTP-II) from human plasma.

Authors:  J H Tollefson; S Ravnik; J J Albers
Journal:  J Lipid Res       Date:  1988-12       Impact factor: 5.922

4.  Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14.

Authors:  J Pugin; C C Schürer-Maly; D Leturcq; A Moriarty; R J Ulevitch; P S Tobias
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

5.  Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions.

Authors:  C E Matz; A Jonas
Journal:  J Biol Chem       Date:  1982-04-25       Impact factor: 5.157

6.  Human granulocytes express a 55-kDa lipopolysaccharide-binding protein on the cell surface that is identical to the bactericidal/permeability-increasing protein.

Authors:  A J Weersink; K P van Kessel; M E van den Tol; J A van Strijp; R Torensma; J Verhoef; P Elsbach; J Weiss
Journal:  J Immunol       Date:  1993-01-01       Impact factor: 5.422

7.  Inactivation of endotoxin by a humoral component. II. Interaction of endotoxin with serum and plasma.

Authors:  R C SKARNES; F S ROSEN; M J SHEAR; M LANDY
Journal:  J Exp Med       Date:  1958-11-01       Impact factor: 14.307

8.  Lipopolysaccharide (LPS) binding protein opsonizes LPS-bearing particles for recognition by a novel receptor on macrophages.

Authors:  S D Wright; P S Tobias; R J Ulevitch; R A Ramos
Journal:  J Exp Med       Date:  1989-10-01       Impact factor: 14.307

9.  Activation of the adhesive capacity of CR3 on neutrophils by endotoxin: dependence on lipopolysaccharide binding protein and CD14.

Authors:  S D Wright; R A Ramos; A Hermanowski-Vosatka; P Rockwell; P A Detmers
Journal:  J Exp Med       Date:  1991-05-01       Impact factor: 14.307

10.  Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14.

Authors:  E Hailman; H S Lichenstein; M M Wurfel; D S Miller; D A Johnson; M Kelley; L A Busse; M M Zukowski; S D Wright
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

View more
  117 in total

1.  Distribution and kinetics of lipoprotein-bound endotoxin.

Authors:  J H Levels; P R Abraham; A van den Ende; S J van Deventer
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  Dual role of lipopolysaccharide (LPS)-binding protein in neutralization of LPS and enhancement of LPS-induced activation of mononuclear cells.

Authors:  T Gutsmann; M Müller; S F Carroll; R C MacKenzie; A Wiese; U Seydel
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

3.  Acute-phase concentrations of lipopolysaccharide (LPS)-binding protein inhibit innate immune cell activation by different LPS chemotypes via different mechanisms.

Authors:  Lutz Hamann; Christian Alexander; Cordula Stamme; Ulrich Zähringer; Ralf R Schumann
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

4.  Influence of lipopolysaccharide-binding protein on pulmonary inflammation in gram-negative pneumonia.

Authors:  Michael A Taddonio; Vladislav Dolgachev; Markus Bosmann; Peter A Ward; Grace Su; Stewart C Wang; Mark R Hemmila
Journal:  Shock       Date:  2015-06       Impact factor: 3.454

5.  Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein.

Authors:  M M Wurfel; E Hailman; S D Wright
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

6.  New approaches to sepsis: molecular diagnostics and biomarkers.

Authors:  Konrad Reinhart; Michael Bauer; Niels C Riedemann; Christiane S Hartog
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

7.  Low endotoxic potential of Legionella pneumophila lipopolysaccharide due to failure of interaction with the monocyte lipopolysaccharide receptor CD14.

Authors:  B Neumeister; M Faigle; M Sommer; U Zähringer; F Stelter; R Menzel; C Schütt; H Northoff
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

Review 8.  The role of CD14 and lipopolysaccharide-binding protein (LBP) in the activation of different cell types by endotoxin.

Authors:  R R Schumann; E T Rietschel; H Loppnow
Journal:  Med Microbiol Immunol       Date:  1994-12       Impact factor: 3.402

9.  Immunoreactivity and bioactivity of lipopolysaccharide-binding protein in normal and heat-inactivated sera.

Authors:  K Mészáros; S Aberle; M White; J B Parent
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

10.  Diagnostic value of lipopolysaccharide-binding protein and procalcitonin for sepsis diagnosis in forensic pathology.

Authors:  Marc Augsburger; Katia Iglesias; Daniel Bardy; Patrice Mangin; Cristian Palmiere
Journal:  Int J Legal Med       Date:  2012-10-13       Impact factor: 2.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.